Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib + Pembrolizumab + Chemotherapy in 1L Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Aug 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
A Phase 3 trial of zoldonrasib in non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Started Aug 2026; status: recruiting.
02
Drugs
zoldonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07777822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07777822.